Which Factors Predict Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Post-Docetaxel?

Autor: Thierry Gil, Peter Schatteman, Marylene Clausse, Jan Van Haverbeke, Joanna Van Erps, Jeroen Mebis, Wim Demey, Marika Rasschaert, Dirk Schrijvers, Lionel D'Hondt, Els Everaert, W. Wynendaele, Bertrand Filleul, Sylvie Rottey, Filip Van Aelst, Joanna Vermeij, Fransien Van Hende, Patrick Werbrouck, Jean-Charles Goeminne, Charles Van Praet, Gino Pelgrims, Nicolaas Lumen, Jolanda Verheezen, Jean Pascal Machiels, Denis Schallier
Přispěvatelé: Laboratory of Molecular and Medical Oncology
Rok vydání: 2017
Předmět:
Male
Oncology
medicine.medical_specialty
Taxoids/therapeutic use
Urology
Abiraterone Acetate
Abiraterone Acetate/therapeutic use
Prednisone/therapeutic use
Docetaxel
chemotherapy
survival
03 medical and health sciences
chemistry.chemical_compound
Prostate cancer
0302 clinical medicine
Internal medicine
Humans
Medicine
Enzalutamide
030212 general & internal medicine
Survival analysis
Aged
Proportional Hazards Models
Retrospective Studies
Prostatic Neoplasms
Castration-Resistant/drug therapy
Univariate analysis
business.industry
Proportional hazards model
Abiraterone acetate
Prostatic Neoplasms
Retrospective cohort study
Prognosis
medicine.disease
Survival Analysis
Surgery
Prostatic Neoplasms
Castration-Resistant
Treatment Outcome
ROC Curve
chemistry
030220 oncology & carcinogenesis
Prednisone
Taxoids
Human medicine
business
steroids
medicine.drug
Zdroj: Clinical Genitourinary Cancer
ISSN: 1558-7673
DOI: 10.1016/j.clgc.2017.01.019
Popis: Individual patients' survival varies greatly in metastatic castration-resistant prostate cancer. Retrospective analysis of 368 patients treated with docetaxel and starting abiraterone acetate revealed 5 adverse prognostic factors: hemoglobin < 12 g/dL, > 10 metastases, ECOG performance status >= 2, radiographic progression, and time since diagnosis < 90 months. A prognostic model stratifies patients into 3 groups with different estimated survival, which can aid in patient counseling.Abiraterone acetate (AA) increases overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel. However, survival time varies substantially between individuals. Our goal was to identify prognostic factors that better estimate OS. Materials and Methods: This is a retrospective multicentric analysis of 368 patients with mCRPC starting AA with prednisone after docetaxel. Cox proportional hazards statistics were applied. A multivariate model was constructed based on significant univariate predictors by using a manual stepwise forward and backward selection strategy. Model performance was determined by using receiver operating characteristic (ROC) curves. Results: Univariate analysis identified 20 significant OS predictors. A multivariate model was constructed, based on 220 patients, incorporating 5 independent risk factors for decreased OS at the time of AA initiation: hemoglobin 10 metastases (HR 1.80), ECOG performance status >= 2 (HR 1.88), radiographic progression (HR 1.50), and time since diagnosis < 90 months (HR 1.66, all P
Databáze: OpenAIRE
Externí odkaz: